EE03399B1 - Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess - Google Patents

Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess

Info

Publication number
EE03399B1
EE03399B1 EE9700039A EE9700039A EE03399B1 EE 03399 B1 EE03399 B1 EE 03399B1 EE 9700039 A EE9700039 A EE 9700039A EE 9700039 A EE9700039 A EE 9700039A EE 03399 B1 EE03399 B1 EE 03399B1
Authority
EE
Estonia
Prior art keywords
spiro
therapy
preparation
compounds used
azabicyclic compounds
Prior art date
Application number
EE9700039A
Other languages
English (en)
Other versions
EE9700039A (et
Inventor
Charles Gordon John
Conrad Griffith Ronald
John Murray Robert
Balestra Michael
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9417084A external-priority patent/GB9417084D0/en
Priority claimed from GBGB9504627.2A external-priority patent/GB9504627D0/en
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of EE9700039A publication Critical patent/EE9700039A/et
Publication of EE03399B1 publication Critical patent/EE03399B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EE9700039A 1994-08-24 1995-08-22 Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess EE03399B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9417084A GB9417084D0 (en) 1994-08-24 1994-08-24 Compounds useful in therapy
GBGB9504627.2A GB9504627D0 (en) 1995-03-08 1995-03-08 Compounds for use in therapy
PCT/SE1995/000937 WO1996006098A1 (en) 1994-08-24 1995-08-22 Spiro-azabicyclic compounds useful in therapy

Publications (2)

Publication Number Publication Date
EE9700039A EE9700039A (et) 1997-08-15
EE03399B1 true EE03399B1 (et) 2001-04-16

Family

ID=26305509

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700039A EE03399B1 (et) 1994-08-24 1995-08-22 Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess

Country Status (33)

Country Link
US (2) US5902814A (et)
EP (1) EP0777671B1 (et)
JP (1) JP3708962B2 (et)
KR (1) KR100366331B1 (et)
CN (2) CN1056846C (et)
AR (1) AR031828A2 (et)
AT (1) ATE192157T1 (et)
AU (1) AU690735B2 (et)
BR (1) BR9508751A (et)
CA (1) CA2196995C (et)
CZ (1) CZ289512B6 (et)
DE (1) DE69516524T2 (et)
DK (1) DK0777671T3 (et)
EE (1) EE03399B1 (et)
EG (1) EG24222A (et)
ES (1) ES2145922T3 (et)
FI (1) FI112868B (et)
GR (1) GR3033878T3 (et)
HU (1) HUT77352A (et)
IL (1) IL115039A (et)
IS (1) IS1852B (et)
MX (1) MX9701292A (et)
NO (1) NO307707B1 (et)
NZ (1) NZ292289A (et)
PL (1) PL183933B1 (et)
PT (1) PT777671E (et)
RU (1) RU2148058C1 (et)
SA (1) SA95160370B1 (et)
SK (1) SK282366B6 (et)
TR (1) TR199501053A2 (et)
TW (1) TW397837B (et)
UA (1) UA54375C2 (et)
WO (1) WO1996006098A1 (et)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
JP4564135B2 (ja) * 1999-07-26 2010-10-20 住友化学株式会社 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶
AU2001241056A1 (en) * 2000-03-09 2001-09-17 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
JP2004507549A (ja) * 2000-08-28 2004-03-11 コロラド　ステート　ユニバーシティー　リサーチ　ファウンデーション オキサゾリジノン部分を含む化合物およびその使用方法
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
JP2005510482A (ja) * 2001-10-16 2005-04-21 アストラゼネカ・アクチエボラーグ 線維筋痛症候群の治療方法
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2003072135A2 (en) * 2002-02-26 2003-09-04 North Shore-Long Island Jewish Research Insitute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
ATE378048T1 (de) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
NZ545132A (en) * 2003-07-08 2009-07-31 Astrazeneca Ab Spiro[1-azabicyclo[2.2.2.]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
CA2560756A1 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methods and devices for reducing bleed time using vagus nerve stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
JP2008524208A (ja) * 2004-12-15 2008-07-10 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリン受容体リガンド
EP2298410B1 (en) 2004-12-27 2013-10-09 The Feinstein Institute for Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP1833804A1 (en) * 2004-12-28 2007-09-19 AstraZeneca AB Aryl sulphonamide modulators
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
RU2326787C2 (ru) * 2005-11-09 2008-06-20 Сергей Федорович Бокарев Способ управления крылом, помещенным в текучую среду, при его взаимодействии с этой средой и устройство для его осуществления
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
WO2008028903A2 (en) 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
DE102008015999B4 (de) 2008-03-27 2011-04-21 Novar Gmbh Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage
WO2009146030A1 (en) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
US8507516B2 (en) 2009-10-28 2013-08-13 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255B1 (en) 2016-01-20 2025-12-31 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11745039B2 (en) 2016-07-25 2023-09-05 Tonal Systems, Inc. Assisted racking of digital resistance
US10661112B2 (en) 2016-07-25 2020-05-26 Tonal Systems, Inc. Digital strength training
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US10335626B2 (en) 2017-10-02 2019-07-02 Tonal Systems, Inc. Exercise machine with pancake motor
US10589163B2 (en) 2017-10-02 2020-03-17 Tonal Systems, Inc. Exercise machine safety enhancements
US10486015B2 (en) 2017-10-02 2019-11-26 Tonal Systems, Inc. Exercise machine enhancements
US10617903B2 (en) 2017-10-02 2020-04-14 Tonal Systems, Inc. Exercise machine differential
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
WO2020210786A1 (en) 2019-04-12 2020-10-15 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
JP2023512447A (ja) 2020-01-13 2023-03-27 ザ ファインスタイン インスティチューツ フォー メディカル リサーチ 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
US11285355B1 (en) 2020-06-08 2022-03-29 Tonal Systems, Inc. Exercise machine enhancements
US11998804B2 (en) 2021-04-27 2024-06-04 Tonal Systems, Inc. Repetition phase detection
US11878204B2 (en) 2021-04-27 2024-01-23 Tonal Systems, Inc. First repetition detection
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders
US12649059B2 (en) 2022-08-05 2026-06-09 The Feinstein Institutes For Medical Research Methods for reducing bleeding in hemophilia by vagus nerve stimulation to prime platelets
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028351A (en) * 1971-09-07 1977-06-07 Buskine S.A. Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained
CH601304A5 (et) * 1974-02-12 1978-07-14 Buskine Sa
SU495310A1 (ru) * 1974-03-05 1975-12-15 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Хинуклидил-3-диарал(гетерил) карбинолы, про вл ющие антигистаминную, антисеротониновую и антиаллергическую активность и способ их получени
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
GB8816299D0 (en) * 1988-07-08 1988-08-10 Merck Sharp & Dohme Therapeutic agents
US5534520A (en) * 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
IL97726A (en) * 1990-04-10 1994-12-29 Israel Inst Biolog Res Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
US5137895A (en) * 1991-04-29 1992-08-11 A. H. Robins Company, Incorporated 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols

Also Published As

Publication number Publication date
CN1099419C (zh) 2003-01-22
EG24222A (en) 2008-11-10
CN1159808A (zh) 1997-09-17
US6051581A (en) 2000-04-18
PL183933B1 (pl) 2002-08-30
TR199501053A2 (tr) 1996-06-21
SK282366B6 (sk) 2002-01-07
CA2196995C (en) 2008-05-13
KR100366331B1 (ko) 2003-04-10
NZ292289A (en) 1998-05-27
EE9700039A (et) 1997-08-15
ATE192157T1 (de) 2000-05-15
MX9701292A (es) 1997-05-31
CA2196995A1 (en) 1996-02-29
WO1996006098A1 (en) 1996-02-29
IL115039A0 (en) 1995-12-08
GR3033878T3 (en) 2000-11-30
EP0777671A1 (en) 1997-06-11
PT777671E (pt) 2000-08-31
PL318760A1 (en) 1997-07-07
IS4424A (is) 1997-02-03
HK1010370A1 (en) 1999-06-17
FI970762A0 (fi) 1997-02-24
DE69516524T2 (de) 2001-01-18
CZ39297A3 (en) 1997-12-17
BR9508751A (pt) 1997-08-12
CN1284505A (zh) 2001-02-21
DK0777671T3 (da) 2000-07-24
AU3401895A (en) 1996-03-14
SA95160370B1 (ar) 2006-06-04
IS1852B (is) 2003-02-21
NO970800D0 (no) 1997-02-21
AR031828A2 (es) 2003-10-08
EP0777671B1 (en) 2000-04-26
RU2148058C1 (ru) 2000-04-27
FI112868B (fi) 2004-01-30
FI970762L (fi) 1997-02-24
AU690735B2 (en) 1998-04-30
DE69516524D1 (de) 2000-05-31
UA54375C2 (uk) 2003-03-17
HUT77352A (hu) 1998-03-30
CZ289512B6 (cs) 2002-02-13
NO307707B1 (no) 2000-05-15
ES2145922T3 (es) 2000-07-16
JPH10504561A (ja) 1998-05-06
CN1056846C (zh) 2000-09-27
JP3708962B2 (ja) 2005-10-19
IL115039A (en) 2001-08-26
US5902814A (en) 1999-05-11
SK21697A3 (en) 1997-09-10
TW397837B (en) 2000-07-11
NO970800L (no) 1997-02-21

Similar Documents

Publication Publication Date Title
EE9700039A (et) Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess
FI962954A7 (fi) Substituoidut 3-arylideeni-7-atsaoksindoliyhdisteet ja menetelmä niiden valmistamiseksi
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
FI960751A7 (fi) Substituoidut atsaindolylideeniyhdisteet ja menetelmä niiden valmistamiseksi
EE9700153A (et) Heterotsükliga kondenseerunud püridiinid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
FI951305L (fi) Lääketieteellinen materiaali ja menetelmä sen valmistamiseksi
FI941137A7 (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI970918L (fi) Yhdisteet ja menetelmät syövän hoitamiseksi
EE9700060A (et) 2-arüül-asendatud püridiinid,nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
FI964102L (fi) Menetelmä fenolin ja fenolijohdannaisten valmistamiseksi
FI951468A7 (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
FI953919A7 (fi) Pyrrolydeenimetyylijohdannaiset ja menetelmä niiden valmistamiseksi
FI944600A0 (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
FI971268A7 (fi) Menetelmä 1,3-alkaanidiolien ja 3-hydroksialdehydien valmistamiseksi
FI944713L (fi) 4-difenyylimetyylipiperidiinijohdannaisia ja menetelmä niiden valmistamiseksi
FI955426A7 (fi) Pintakäsittelytuotteet ja menetelmät niiden valmistamiseksi
FI951060L (fi) Formulaatioita ja hoitomenetelmiä
EE9700288A (et) Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
FI972235L (fi) Menetelmä triaryylietyleenijohdannaisten käyttämiseksi osteoporoosin hoidossa ja ehkäisyssä
FI931414A7 (fi) Imidatsolijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
EE03878B1 (et) 5-O-desosaminüül-6-O-metüülerütronoliid A derivaadid, nende valmistamismeetod ja kasutamine bioaktiivsete ühendite valmistamiseks
FI964901L (fi) Menetelmä alfa-metoksi-iminokarboksyylihappometyyliamidien valmistamiseksi ja menetelmässä käytettyjä välituotteita
FI965008L (fi) Koostumukset ja menetelmät kasvainten hoitamiseksi
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
FI905173A7 (fi) Diatsabisykloamiiniyhdisteet ja menetelmä niiden valmistamiseksi

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

MM4A Lapsed by not paying the annual fees

Effective date: 20090822